Financial Statements · From SEC 10-K & 10-Q XBRL Filings
ResMed Inc. Revenue & Financial Statements
ResMed Inc. reported revenue of $5.1B for the fiscal year ended June 30, 2025, up 9.8% year over year, with net income of $1.4B and diluted EPS of $9.51.
- Company
- ResMed Inc. RMD · NYSE
- Latest fiscal year
- FY ended Jun 30, 2025
- Statements
- Income · Balance Sheet · Cash Flow — 5 fiscal years, 8 quarters
Income Statement
Annual, as reported in 10-K filings. Values in USD.
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | 3.2B | (22.3M) | (47.4M) | 4.7B | 5.1B |
| Cost of revenue | 1.4B | 1.6B | 1.9B | 2.0B | 2.1B |
| Gross profit | 1.8B | 2.0B | 2.4B | 2.7B | 3.1B |
| Operating income | 903.7M | 1.0B | 1.1B | 1.3B | 1.7B |
| Pretax income | 71.9M | (85.9M) | 128.6M | 181.1M | 359.7M |
| Net income | 474.5M | 779.4M | 897.6M | 1.0B | 1.4B |
| Diluted EPS | 3.24 | 5.30 | 6.09 | 6.92 | 9.51 |
| EBITDA | 982.1M | 1.1B | 1.2B | 1.4B | 1.8B |
Quarterly
| USD | Q4 '24 | Q1 '24 | Q3 '24 | Q2 '24 | Q3 '25 | Q4 '25 | Q1 '25 | Q2 '25 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1.2B | 1.2B | — | 1.3B | 1.3B | 1.3B | 1.3B | 1.4B |
| Cost of revenue | 507.7M | 507.3M | — | 530.8M | 525.3M | 527.9M | 514.8M | 544.1M |
| Gross profit | 715.5M | 717.2M | — | 751.3M | 766.4M | 820.1M | 820.8M | 878.7M |
| Operating income | 381.2M | 387.3M | — | 417.2M | 426.3M | 454.5M | 446.5M | 491.7M |
| Pretax income | 357.7M | 383.5M | — | 418.3M | 417.7M | 458.1M | 446.8M | 496.1M |
| Net income | 292.2M | 311.4M | 344.6M | 344.6M | 365.0M | 379.7M | 348.5M | 392.6M |
| Diluted EPS | 1.98 | 2.11 | — | 2.34 | 2.48 | 2.58 | 2.37 | 2.68 |
| EBITDA | 424.9M | 432.0M | — | 463.7M | 469.9M | 518.2M | 494.2M | 541.5M |
Balance Sheet
Fiscal year-end snapshots. Values in USD.
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Total assets | 4.7B | 5.1B | 6.8B | 6.9B | 8.2B |
| Current assets | 1.6B | 1.9B | 2.4B | 2.4B | 3.5B |
| Cash & equivalents | 295.3M | 273.7M | 227.9M | 238.4M | 1.2B |
| Total liabilities | 1.8B | 1.7B | 2.6B | 2.0B | 2.2B |
| Current liabilities | 911.8M | 689.3M | 758.5M | 910.7M | 1.0B |
| Long-term debt | — | — | — | — | — |
| Total debt | 12.0M | 9.9M | 9.9M | 9.9M | 9.9M |
| Stockholders’ equity | 2.9B | 3.4B | 4.1B | 4.9B | 6.0B |
| Net debt | (283.3M) | (263.8M) | (218.0M) | (228.5M) | (1.2B) |
Cash Flow Statement
Annual, as reported in 10-K filings. Values in USD.
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Operating cash flow | 736.7M | 351.1M | 693.3M | 1.4B | 1.8B |
| Investing cash flow | (158.5M) | (229.9M) | (1.2B) | (269.8M) | (200.0M) |
| Financing cash flow | (764.6M) | (128.4M) | 422.9M | (1.1B) | (606.3M) |
| Capital expenditure | 102.7M | 134.8M | 119.7M | 99.5M | 89.9M |
| Free cash flow | 634.0M | 216.3M | 573.6M | 1.3B | 1.7B |
| Dividends paid | 226.7M | 245.3M | 258.3M | 282.3M | 310.9M |
| Stock-based compensation | 63.9M | 65.3M | 71.1M | 80.2M | 91.7M |
Figures are parsed from SEC XBRL company facts and may be derived where issuers report year-to-date values (quarterly figures differenced; Q4 computed as FY minus Q3). Fiscal periods follow each company's fiscal calendar, not calendar years. Historical fact, not investment advice — verify with official SEC filings.
Every RMD filing, connected
Financials beside price, insider trades, and 8-K events — with alerts the moment something new is filed.